POSACONAZOLE — HIKMA, approved 2024-10-24 (ANDA208773).
12,049 reports across the top reactions. These are spontaneously reported events from the FDA Adverse Event Reporting System — they reflect reporting volume, not incidence or frequency, and a report does not mean the drug caused the event.